Inhibrx (INBX) Competitors $13.33 -0.77 (-5.46%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$13.38 +0.05 (+0.41%) As of 06:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. REPL, COGT, DAWN, EOLS, AVDL, AVXL, PHVS, CDMO, QURE, and ABCLShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Replimune Group (REPL), Cogent Biosciences (COGT), Day One Biopharmaceuticals (DAWN), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Anavex Life Sciences (AVXL), Pharvaris (PHVS), Avid Bioservices (CDMO), uniQure (QURE), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Replimune Group Cogent Biosciences Day One Biopharmaceuticals Evolus Avadel Pharmaceuticals Anavex Life Sciences Pharvaris Avid Bioservices uniQure AbCellera Biologics Replimune Group (NASDAQ:REPL) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Do institutionals & insiders have more ownership in REPL or INBX? 92.5% of Replimune Group shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 8.8% of Replimune Group shares are held by company insiders. Comparatively, 22.2% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is REPL or INBX more profitable? Replimune Group's return on equity of -54.84% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% Inhibrx N/A -113.74%-80.56% Which has preferable earnings & valuation, REPL or INBX? Inhibrx has higher revenue and earnings than Replimune Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-2.57Inhibrx$200K964.83-$154.96MN/AN/A Does the media refer more to REPL or INBX? In the previous week, Inhibrx had 1 more articles in the media than Replimune Group. MarketBeat recorded 4 mentions for Inhibrx and 3 mentions for Replimune Group. Inhibrx's average media sentiment score of 1.30 beat Replimune Group's score of 1.04 indicating that Inhibrx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer REPL or INBX? Replimune Group presently has a consensus target price of $19.43, indicating a potential upside of 146.24%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts clearly believe Replimune Group is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor REPL or INBX? Replimune Group received 138 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 64.02% of users gave Replimune Group an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% InhibrxOutperform Votes3158.49% Underperform Votes2241.51% SummaryReplimune Group beats Inhibrx on 9 of the 14 factors compared between the two stocks. Remove Ads Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.97M$2.97B$5.54B$7.49BDividend YieldN/A1.53%5.35%4.04%P/E RatioN/A30.4323.2518.07Price / Sales964.83383.26361.2686.83Price / CashN/A168.6838.1634.64Price / BookN/A3.646.493.99Net Income-$154.96M-$72.06M$3.21B$247.18M7 Day Performance-6.91%-10.59%-6.42%-6.42%1 Month Performance-1.84%-16.74%-0.68%-7.44%1 Year Performance-62.00%-30.77%6.05%-4.31% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx1.8943 of 5 stars$13.33-5.5%N/A-62.0%$204.11M$200,000.000.00166News CoveragePositive NewsREPLReplimune Group3.553 of 5 stars$11.05+2.1%$19.43+75.8%+11.8%$851.02MN/A-3.60210Positive NewsGap DownCOGTCogent Biosciences2.0497 of 5 stars$7.40+3.4%$14.43+95.0%-22.6%$842.49MN/A-2.9880Gap DownDAWNDay One Biopharmaceuticals2.9829 of 5 stars$8.31+1.0%$34.57+316.0%-50.6%$842.26M$131.16M-8.0760Analyst ForecastGap DownEOLSEvolus3.7308 of 5 stars$13.00-0.2%$24.67+89.7%-16.1%$826.63M$266.27M-14.29170Gap DownAVDLAvadel Pharmaceuticals3.1465 of 5 stars$8.53-0.5%$19.88+133.0%-55.8%$824.25M$169.12M-10.8070Gap DownAVXLAnavex Life Sciences3.3957 of 5 stars$9.61-1.3%$44.00+357.9%+79.7%$817.47MN/A-17.4740News CoveragePositive NewsGap DownPHVSPharvaris1.2447 of 5 stars$15.47+0.5%$40.50+161.8%-34.4%$808.93MN/A-5.5330Upcoming EarningsNews CoverageGap DownCDMOAvid Bioservices0.9648 of 5 stars$12.50+0.1%$12.25-2.0%+89.6%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.4405 of 5 stars$14.77+7.8%$38.89+163.3%+83.3%$798.72M$27.12M-2.98500Analyst ForecastAnalyst RevisionNews CoverageABCLAbCellera Biologics1.971 of 5 stars$2.59+6.1%$7.00+170.3%-52.3%$771.79M$28.83M-4.25500News CoverageGap Down Remove Ads Related Companies and Tools Related Companies Replimune Group Alternatives Cogent Biosciences Alternatives Day One Biopharmaceuticals Alternatives Evolus Alternatives Avadel Pharmaceuticals Alternatives Anavex Life Sciences Alternatives Pharvaris Alternatives Avid Bioservices Alternatives uniQure Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INBX Stock Free INBX Stock Alerts